This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

APEN Stock Overview

Apollo Endosurgery, Inc., a medical technology company, focuses on the design, development, and commercialization of medical devices for gastrointestinal therapeutic endoscopy. More details

APEN fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	2/6
Past Performance	0/6
Financial Health	5/6
Dividends	0/6

Rewards

Revenue is forecast to grow 32.05% per year

Risk Analysis

Currently unprofitable and not forecast to become profitable over the next 3 years

Shareholders have been diluted in the past year

Community vs My Fair Value

Create Narrative

Select a narrative for quick price alerts from the community, or create your own.

Apollo Endosurgery, Inc. Competitors

Cutera

OTCPK:CUTR.Q

US$167.5k

SI-BONE

NasdaqGM:SIBN

US$744.5m

IRADIMED

NasdaqGM:IRMD

US$648.6m

ViewRay

OTCPK:VRAY.Q

US$18.3k

Price History & Performance

Summary of share price highs, lows and changes for Apollo Endosurgery
Historical stock prices
Current Share Price	US$10.00
52 Week High	US$10.30
52 Week Low	US$3.49
Beta	2.32
1 Month Change	0.50%
3 Month Change	1.11%
1 Year Change	67.79%
3 Year Change	360.83%
5 Year Change	70.94%
Change since IPO	-17.76%

Is Apollo Endosurgery (NASDAQ:APEN) Using Debt Sensibly?

Apr 03

Is Apollo Endosurgery (NASDAQ:APEN) Weighed On By Its Debt Load?

Nov 30

Recent updates

What Percentage Of Apollo Endosurgery, Inc. (NASDAQ:APEN) Shares Do Insiders Own?

Mar 03

Trade Alert: Neil Gagnon At Apollo Endosurgery, Inc. (NASDAQ:APEN), Has Just Spent US$146k Buying 2.8% More Shares

Feb 10

We Think Apollo Endosurgery (NASDAQ:APEN) Has A Fair Chunk Of Debt

Jan 31

If You Had Bought Apollo Endosurgery's (NASDAQ:APEN) Shares Three Years Ago You Would Be Down 36%

Dec 27

Is It Too Late To Consider Buying Apollo Endosurgery, Inc. (NASDAQ:APEN)?

Dec 01

Shareholder Returns

	APEN	US Medical Equipment	US Market
7D	0.8%	2.0%	1.3%
1Y	67.8%	7.9%	8.2%

Return vs Industry: APEN exceeded the US Medical Equipment industry which returned -13.3% over the past year.

Return vs Market: APEN exceeded the US Market which returned -11.4% over the past year.

Price Volatility

Is APEN's price volatile compared to industry and market?
APEN volatility
APEN Average Weekly Movement	0.5%
Medical Equipment Industry Average Movement	9.6%
Market Average Movement	7.9%
10% most volatile stocks in US Market	16.4%
10% least volatile stocks in US Market	4.1%

Stable Share Price: APEN has not had significant price volatility in the past 3 months.

Volatility Over Time: APEN's weekly volatility has decreased from 12% to 1% over the past year.

About the Company

Founded	Employees	CEO	Website
2005	202	Chas McKhann	www.apolloendo.com

Apollo Endosurgery, Inc., a medical technology company, focuses on the design, development, and commercialization of medical devices for gastrointestinal therapeutic endoscopy. The company offers OverStitch and OverStitch Sx Endoscopic Suturing Systems that enable advanced endoscopic procedures by allowing physicians to suture and secure the approximation of tissue through a flexible endoscope. It also provides Orbera, an intragastric balloon system that reduces stomach capacity causing patients to consume less following the procedure, and delays gastric content emptying, which assists the patient in losing weight under the Orbera Intragastric Balloon System, BIB, and Orbera365 Managed Weight Loss System brands.

Apollo Endosurgery, Inc. Fundamentals Summary

How do Apollo Endosurgery's earnings and revenue compare to its market cap?
APEN fundamental statistics
Market cap	US$579.72m
Earnings (TTM)	-US$39.84m
Revenue (TTM)	US$76.86m

7.5x

P/S Ratio

-14.6x

P/E Ratio

Is APEN overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
APEN income statement (TTM)
Revenue	US$76.86m
Cost of Revenue	US$34.43m
Gross Profit	US$42.43m
Other Expenses	US$82.27m
Earnings	-US$39.84m

Last Reported Earnings

Dec 31, 2022

Next Earnings Date

n/a

Earnings per share (EPS)	-0.69
Gross Margin	55.20%
Net Profit Margin	-51.84%
Debt/Equity Ratio	164.7%

How did APEN perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2023/04/06 14:06
End of Day Share Price	2023/04/03 00:00
Earnings	2022/12/31
Annual Earnings	2022/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Apollo Endosurgery, Inc. is covered by 8 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Matthew Hewitt	Craig-Hallum Capital Group LLC
Frank Takkinen	Lake Street Capital Markets, LLC
Suraj Kalia	Northland Capital Markets

This company has been acquired

APEN Stock Overview

Rewards

Risk Analysis

Apollo Endosurgery, Inc. Competitors

OTCPK:CUTR.Q

US$167.5k

NasdaqGM:SIBN

US$744.5m

NasdaqGM:IRMD

US$648.6m

OTCPK:VRAY.Q

US$18.3k

Price History & Performance

Recent News & Updates

Is Apollo Endosurgery (NASDAQ:APEN) Using Debt Sensibly?

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target decreased to US$11.75

Is Apollo Endosurgery (NASDAQ:APEN) Weighed On By Its Debt Load?

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus forecasts updated

Recent updates

Is Apollo Endosurgery (NASDAQ:APEN) Using Debt Sensibly?

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target decreased to US$11.75

Is Apollo Endosurgery (NASDAQ:APEN) Weighed On By Its Debt Load?

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus forecasts updated

Is Apollo Endosurgery (NASDAQ:APEN) Using Too Much Debt?

Apollo Endosurgery: Collect Shares At A Discount Following Q2 Earnings

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

First quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat

CFO, Secretary & Treasurer recently bought US$229k worth of stock

Is Apollo Endosurgery (NASDAQ:APEN) Using Debt Sensibly?

Full year 2021 earnings: EPS exceeds analyst expectations

Consensus forecasts updated

Price target decreased to US$12.67

Third quarter 2021 earnings released: US$0.23 loss per share (vs US$0.11 loss in 3Q 2020)

CEO, President & Director recently sold US$504k worth of stock

CEO, President & Director recently sold US$504k worth of stock

Chief Financial Officer recently bought US$219k worth of stock

Consensus forecasts updated

Price target increased to US$14.00

Second quarter 2021 earnings released: US$0.11 loss per share (vs US$0.30 loss in 2Q 2020)

Is Apollo Endosurgery, Inc. (NASDAQ:APEN) Trading At A 20% Discount?

Apollo Endosurgery: New Management Bounce Makes Weight Loss Specialist A Buy

Insider recently sold US$129k worth of stock

Price target increased to US$11.25

First quarter 2021 earnings released: US$0.17 loss per share (vs US$0.49 loss in 1Q 2020)

Is Apollo Endosurgery (NASDAQ:APEN) A Risky Investment?

A Look At The Intrinsic Value Of Apollo Endosurgery, Inc. (NASDAQ:APEN)

Independent Chairman of the Board recently bought US$59k worth of stock

What Percentage Of Apollo Endosurgery, Inc. (NASDAQ:APEN) Shares Do Insiders Own?

New 90-day high: US$6.10

Full year 2020 earnings released: US$0.99 loss per share (vs US$1.27 loss in FY 2019)

Insider recently bought US$86k worth of stock

Revenue beats expectations, earnings disappoint

Insider recently bought US$146k worth of stock

Trade Alert: Neil Gagnon At Apollo Endosurgery, Inc. (NASDAQ:APEN), Has Just Spent US$146k Buying 2.8% More Shares

New 90-day high: US$4.86

We Think Apollo Endosurgery (NASDAQ:APEN) Has A Fair Chunk Of Debt

If You Had Bought Apollo Endosurgery's (NASDAQ:APEN) Shares Three Years Ago You Would Be Down 36%

Is It Too Late To Consider Buying Apollo Endosurgery, Inc. (NASDAQ:APEN)?

New 90-day high: US$2.30

Analysts increase revenue estimates to US$40.2m

Third quarter 2020 earnings released: US$0.11 loss per share

Revenue beats expectations, earnings disappoint

New 90-day high: US$1.79

Shareholder Returns

Price Volatility

About the Company

Apollo Endosurgery, Inc. Fundamentals Summary

7.5x

-14.6x

Earnings & Revenue

Company Analysis and Financial Data Status

Data Sources

Analysis Model and Snowflake

Industry and Sector Metrics

Analyst Sources